Interactions of the H1 antihistamines

Journal of Investigational Allergology and Clinical Immunology

Volumn 16, Issue SUPPL. 1, 2006, Pages 29-36

  Bartra, J ^a   Valero, A L ^a   Del Cuvillo, A ^b   Davila I ^c   Jauregui I ^d   Montoro, J ^e   Mullol, J ^a   Sastre, J ^f  

^a HOSPITAL CLÍNIC   (Spain)

^b Clinica Dr Lobaton   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

^e HOSPITAL DE LA PLANA   (Spain)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CETIRIZINE; CIMETIDINE; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DESLORATADINE; DIPHENHYDRAMINE; EPINASTINE; ERYTHROMYCIN; FLUOXETINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; METOPROLOL; MIZOLASTINE; NEUROLEPTIC AGENT; ORGANIC ANION TRANSPORTER; RUPATADINE; TERFENADINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL; ZILEUTON; CYP3A4 PROTEIN, HUMAN; ORGANIC ANION TRANSPORTER 2; UNCLASSIFIED DRUG;

DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ECG ABNORMALITY; ENZYME SUBSTRATE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; RECOMMENDED DRUG DOSE; REVIEW; TORSADE DES POINTES; DRUG EFFECT; DRUG INTERACTION; PHYSIOLOGY;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS; HUMANS; ORGANIC ANION TRANSPORT POLYPEPTIDE C;

EID: 33846048900     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. a edición. Barcelona: Ed. Masson. 1992; pp.
2. Brodie MJ, Feely J. Adverse drug interactions. Br Med J 1988; 296: 845-849.
3. Gonzalez FJ. The molecuylar biology of Cytochrome P450s. Pharmacol Rev 1988; 40: 244-276.
4. Gram TE, Okine LK, Gram TA. The metabolism of xenobiotics by certain extrahepatic organs and its relation to toxicity. Ann Rev Pharmacol toxicol 1986; 26: 259-291.
5. Guenguerich FP. Characterization of human microsomal cytochrome P450 enzimes. Annu Rev Pharmacol Toxicol 1989; 29: 241-264.
6. Wrighton SA, Stevens JC. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
7. Shimada T, Yamazaki H, Mimura M, Inui Y, Guenguerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxical chemical: studies with liver microsomes from 30 japanese and 30 caucasians. J Pharmacol Exp Ther : 1994; 270: 414-423.
8. Gaedik A, Blue M, Gaedir R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquime/Sparteine polymorphism. Am J Hum Genet 1991; 48: 943-950.
9. Honig PK, Smith JE, Worthman DC, Zamani K, Cantinela LR. Population varability in the pharmacokinetics of terfenadine: the case for a pseduopolymorphism with clinical implication. Drug Metab Drug Interact 1994; 11: 161-168.
10. Matzke GR, Halstenson CE, Opsahl JA, Hilbert J, Perentesis G, Radwanski E, Zampaglione N. Pharmacokinetics of loratadine in patients with renal insufficiency J Clin Pharmacol 1990; 30: 364-371.
11. Molimard M, Diquet B, Strolin Benedetti M. Comparison of pharmacokinetis and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fund Clin Pharmacol 2004; 18: 399-411.
12. Drescher S, Schaeffeler E, Hitzk M, et al. MDR1 gene polymorphisms and disposition of the p-glycoprotein substrate fexofenadine. Br. J. Pharmacol. 2002; 53:526-534.
13. Xie R, Knuth DM, Tan L. Fexofenadine and midazolam disposition in relation to genetic polymorphisms of CYP3A, PXR and P-glycoprotein P19 (PGP). Clin. Pharmacol. Ther. 2003; 73: 19-23.
14. Lin JH, Yamazaki M. Role of p-glycoprotein in pharmacokinetics: clinical implications. ClinPharmacokinet 2003; 42: 59-98.
15. Fischer GA, Lum BL, Sikik BI. Pharmacological cointeractions in the modulation of multidrug resistance. Eur J Cancer 1996; 32: 1082-1088.
16. Schwarz UI, Krappweich P, Gramatte T, Kirch W. Erithromicin-tanilolol interaction increases oral biovailability in humans. Eur J Clin Pharmacol 1998; 65: A23.
17. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic transporting polypetide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002; 71: 11-20.
18. Kamath AV, Yao M, Zhang Y, Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci. 2005; 94: 233-239.
19. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998; 26: 536-539.
20. Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003; 31:312-318.
21. Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. Curr Drug Metab 2003; 4: 105-129.
22. Lessard E, Yessine MA, Hamelin BA, Gauvin C, Labbe L, O'Hara G, LeBlanc J, Turgeon J. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21: 175- 184.
23. Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P, Allaire J, Dumesnil J, Turgeon J. Significant interaction between the non-prescription antihistamine diphenydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP 2D6 activity. Clin Pharmacol Ther 2000; 67: 466-477.
24. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989; 298:325.
25. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 1993; 45: 401-406.
26. Honig PK, Worthman DC, Zamani K, Conner DP, Mullin JC, Cantinela LR. Terfenadine-ketoconazole interaction. Pharmakokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-1518.
27. Honig PK, Worthman DC, Zamani K, Cantinela LR. Comporison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfen adine steady-state pharmakokinetic and electrocardiographic parameters. Drug Invest 1994; 7:148-156.
28. Marchiando RJ, Cook MD, Jue SG. Probable terfenadinefluoxetine- associated cardiac toxicity. Ann Pharmacother 1995; 29: 937-938.
29. Fournier P, Pacouret G, Charbonnier B. A new cause of torsade de pointes. Combination of terfenadine and troleandomycine. Ann cardiol Angeiol (Paris) 1993; 42: 249-252.
30. Awni WM, Cavanaugh JH, Leese P, Kasier J, Cao G, Locke CS, Dube LM. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol 1997; 52: 49-54.
31. Jha RJ. Thiazolidinediones, the new insulin enhancers. Clin Exp Hypertens 1999; 21: 157-166.
32. Granberry MC, Schneider EF, Fonseca VA. The role of troglitazone in treating the insulin resistance syndrome. Pharmacoterapy 1998; 18: 973-987.
33. Ling KHJ, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. Metabolism of terfenadine associated with CYP3A4 activity in human hepatic microsomes. Drug Metab Dispos 1995; 23: 631-636.
34. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexafenadine. Clin Pharmacol Ther 2001; 69: 114-121.
35. Craig-McFeely PM, Achayra NV, Shakir SA. Evaluation of the safety of fexafenadine from experience gained in general practice use in England in 1997. Eur J Clin Pharmacol 2001; 57: 313-320.
36. Prait CM, Mason J, Rusell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl . Am J Cardiol 1999; 83: 1451-1454.
37. Craft TM. Torsade de pointes after astemizole overdose. BMJ 1986; 292:660.
38. Snook J, Boothman BD, Watkins J, Collins JD. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 1988; 42: 257-259.
39. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 1997; 96: 144-146.
40. Goos JE, Ramo BW, Blake K. Torsade de pointes associated with astemizole (Hismanal) therapy. Arch Intern Med 1993; 153: 2705.
41. Meuldermans JH, Lauwers W, Hurkmans R, Swysen E, Heykants J. Excretion and biotransformation of astemizole in rats, guinea pigs, dogs, and man. Drug Dev Res 1986; 8:37-51.
42. Slater JW, Zechnich AD, Haxby DG. Second generation antihistamines, a comparative review. Drugs 1999; 57: 31-47.
43. Handley DA, McCullough JR, Fang KO, Wright SE, Smith ER. Comparative antihistaminic effects of astemizole and a metabolite, norastemizole. Ann Allergy Asthma immunol 1997; 78: 144.
44. Katchen B, Cramer J, Chung M. Disposition of 14C-SCH 29851 in humans. Ann Allergy 1985; 55:393.
45. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Biochem Pharmacol 1996; 51: 165-172.
46. Affrime MB. Loratadine: cardiovascular safety. In: Affrime MB, Barbey JT, Cleeman L, et al., editors. Cardiovascular safety of H1 antihistamines: a roundtable discussion. Kenilworth, NJ: Schering Plough, 1996: 14-21.
47. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, Cayen MN, Affrime MB. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharm Ther 1995; 58: 269-278.
48. Carr RA, Edmonds A, Shi H, Locke CS, Gustavson LE, Craft JC, Harris SI, Palmer R. Steady-state pharmacokinetics and electrocardiographic phamacodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrob Agents Chemother 1998; 42: 1176-1180.
49. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, Affrime MB. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazol or cimetidine. Br J Clin Pharmacol 2000; 50: 581-589.
50. Abernethy DR, Barbey JT, Frane J, Brown KS, Feirrera J, Ford N, Salazar DE. Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 2001; 69: 96-103.
51. Barbey J: Loratadine/nefazodone interaction. Clin Pharmacol Ther 2002; 71:403.
52. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56: 7-13.
53. Banfield C, Hunt T, Reyderman L, Stalkevich P, Padhi D, Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002; 41 (Suppl 1): 29-35.
54. Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002; 41 (Suppl 1):37-44.
55. Hashizume T, Mise M, Terauchi Y, O L, Fujii T, Miyazaki H, Inaba T. N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 1998; 26: 566-571.
56. Wiseman LR, Faulds D. Ebastine, a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996; 51: 260-277.
57. Hey JA, del Prado M, Kreutner W, Egan RW. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneimittelforschung. 1996; 46:159-63.
58. Yap TG, Camm AJ. The current cardiac safety situation with antihistamines. Clin Exp Allergy 1999; 29 (Suppl 1): 15-24.
59. Simons FER. Mizolastine: antihistaminic activity from preclinical data to clinical evaluation. Clin Exp Allergy 1999; 29: 3-8.
60. Deschamp C, Dubruc C, Mentre F, Rosensweig P. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model. Clin Pharmacol Ther 2000; 68: 647-657.
61. Delauche-Cavalier MC, Chaufour S, Guerault E, Lacroix A, Murrieta M, Wajman A. QT interval monitoring during clinical studies with mizolastine, a new antihistamine. Clin Exp Allergy 1999; 29: 206-211.
62. Horak F, Stubner UP. Comparative tolerability of second generation antihistamines. Drug Saf 1999; 20: 385-401.
63. Dubuske LM. Second-generation antihistamines: the risk of ventricular arrythmia. Clin Ther 1999; 21: 281-295.
64. Kishimoto W, Hiroi T, Sakai K, Funae Y, Igarashi T. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol 1997; 52 (Suppl 37): 67.
65. Ohtani H, Kotaki H, Sawada Y, Iga T. A comparative pharmacokinetic- pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadina in rats. J Pharm Pharmacol 1997; 49: 458-462.
66. Sale M, Woosley RL, Thakker K, Phillips K, Caridi F, Chung M. Effects of cetirizine and erythromycin, alone and in combination, on QT interval and pharmacokinetics in healthy subjects. Ann Allergy Asthma immunol 1996; 76:93
67. Sale M, Woosley RL, Thakker K, Phillips K, Caridi F, Chung M. A randomized, placebo-controlled, multiple-dose study to evaluate the electrocardiographic and pharmacokinetic interactions of azithromycin and cetirizine. Ann Allergy Asthma Immunol 1996; 76:93.
68. Sale ME, Barbey JT, Woosley RL, Edwards D, Yeh J, Thakker K, Chung M. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994; 56: 295-301.
69. Baltes E, Coupez R, Giezek H, Voss G, Meyerhoff C, Strolin Benedetti M. Absortion and disposition of levocetirizine, the enantiomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001; 15: 269-277.
70. Izquierdo I, Merlos M, García-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today. 2003; 39: 451-468.
71. Nicolas JM. The metabolic profile of second-generation antihistamines. Allergy 2000; 55: 46-52.
72. Strolin-Benedetti M, Whomsley R, Baltes E. Pharmacokinetic drug-drug interactions invovolving H1 antihistamines in humans, in: Marone G. (Ed.). Clinical immunology and allergy in medicine (proocedings EAACI 2002 congress), JGC Editions, Napples, Italy,2004 pp.625-632.
73. Wang E, Casciano CN, Clement RP, Johnson WW. 36 Evalouation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 2001; 29: 1080-1083.
74. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107: 751-762.
75. Lebrun-Vignes, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine. Clin Pharmacokin 2001; 40: 501-507.
76. Whomsley R, Gerin B, Brochot A, Strolin Benedetti M, Baltes E. Transport characteristics of cetirizine and levocetirizine in Caco-2 cell monolayers. Allergy 2003; 58: 274.
77. Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1- antagonists. Drug Metab Dispos 2003; 31: 312-318.
78. Ramu A, Ramu N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 1992; 30: 165-173.
79. Favreau LV, Johnson WW, Chu L, Soares A, Clement RP, White RE. Desloratadine is not transported by human organic anion transport polypeptide A. Ann Allergy Asthma Immunol 2003; 90: 122.
80. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 2005; 77: 17-23.
81. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice interactions. Br J Clin Pharmacol 1998; 46: 101-110.
82. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion- pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139-145.
83. Slaughter RL, Edwars DJ. Recent Advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619-624.
84. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S. Grapefruit juice enhances the bioavalilability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45: 355-359.
85. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoproteinmediated drug transport. Pharm Res 1999; 16:478-485.
86. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933-942.
87. Ubeaud G, Hagenbach J, Vandenschrieck S, Jung L, Koffel JC. In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci 1999; 65: 1403-1412.
88. Edwards DJ, Bellevue FH III, Woster PM. Identification of 6′-7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287-1290.
89. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit juice-felodipine interaction: effects of naringin and 6′7′- dihydroxybergamottin in humans. Clin Pharmacol Ther 1998; 64: 248-256.
90. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice. Furanocumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7:391-396.
91. Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002; 41: 311-318.
92. Zhao XJ, Yokoyama H, Chiba K,Wanwimolruk S, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther 1996; 279: 1327-1334.
93. Food and Drug Administration. Labeling guidance for astemizole tablets, 1997.